Instituto de Investigación Hospital 12 de Octubre

What Instituto de Investigación Hospital 12 de Octubre does

The Instituto de Investigación Hospital 12 de Octubre (i+12) is a public, non-profit multidisciplinary biomedical research institute founded on 15 December 2009 and headquartered within the Hospital Universitario 12 de Octubre campus in Madrid. It operates as an accredited Instituto de Investigación Sanitaria under the Instituto de Salud Carlos III framework — one of only 36 such institutes in Spain, with reaccreditations in 2016, 2021, and January 2026 — and is governed through the FIBH12O foundation as a multi-institutional consortium that includes Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Universidad Autónoma de Madrid, CIEMAT, Universidad Europea, and Universidad Politécnica de Madrid. The institute organizes its work into 68 research groups across 9 scientific areas (Cancer; Chronic Diseases and Transplantation; Rare and Genetic-Based Diseases; Digital Transformation and Care Innovation; Cardiovascular; Inflammatory Diseases and Immune Disorders; Infectious Diseases and AIDS; Neurosciences and Mental Health; and a Transversal Area), and is supported by specialized technical platforms including an authorized national-registry biobank (B.0000657), flow cytometry, genomics, proteomics, bioinformatics (NGS analysis on a Quimera GPU cluster with up to 130TB of storage), confocal microscopy, an AAALAC-equivalent animal facility, clinical research support, and an advanced training/simulation center. Revenue is generated through ISCIII and Comunidad de Madrid public institutional funding, European Commission grants (Horizon Europe, ERDF), competitive national research grants, clinical trial contracts with pharmaceutical sponsors, fee-for-service technical-platform tariffs published online, donations channeled through FIBH12O, and innovation-transfer income. The institute has produced a portfolio of granted patents (including 12CLIP, Datify, Coherent, and multiple miRNA prognostic signatures) and four biotech spin-offs — Altum Sequencing, STAb Therapeutics, TNC Terapia, and Danae Urogenomics — commercializing work in liquid-biopsy oncology detection, cellular therapy, precision nutrition for cancer patients, and urine-based bladder cancer diagnostics, with additional technology transfer managed through the Unidad de Apoyo a la Innovación (UAI i+12).

Name

Instituto de Investigación Hospital 12 de Octubre

Legal name

Instituto de Investigación Hospital 12 de Octubre

Website

https://imas12.es

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

51–100 employees

Short description

The Instituto i+12 is a public, non-profit biomedical research institute in Madrid, accredited by ISCIII, coordinating 68 research groups across 9 scientific areas and serving hospital clinicians, university researchers, pharmaceutical trial sponsors, and patients.

Ownership category

akta.pro rank

Product category

Biomedical Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (6215)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI)

akta.pro secondary industries

Clinical Research & Trial Central Laboratories (HLAFAMAL), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), Translational Medicine & Biomarkers (HLAIALAF)

Keywords

• Biomedical research services
• Clinical research support
• Biobank services
• Translational research
• Health research institute

Headquarters

HQ city

Madrid

HQ country

Spain

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Public Institutional Funding: Core funding from public institutions including Instituto de Salud Carlos III, European Commission (Horizon Europe, ERDF), Plan Estatal de Investigación, and regional government funding through Comunidad de Madrid
2. Research Grants and Contracts: Competitive research grants from national and international funding bodies including CDTI, CIBER networks, and thematic research networks. Clinical trial contracts with pharmaceutical sponsors
3. Donations: Anonymous donations up to 100 euros and identified donations with tax-deductible certificates through FIBH12O foundation. Donations support specific research areas or general research activities
4. Technical Services Fees: Fee-for-service model for biobank, bioinformatics, cytometry, genomics, proteomics, microscopy, and animal facility services. Published tariffs for research support services
5. Innovation Transfer: Revenue from spin-offs, licensed technologies, patents, and commercialization of research results through the Innovation Support Unit

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

The Instituto i+12 operates as an accredited biomedical research institute delivering multidisciplinary translational research through 68 research groups across 9 scientific areas. It provides shared research infrastructure including biobank, genomics, proteomics, cytometry, bioinformatics, microscopy, and animal facility services to affiliated researchers, hospital clinicians, and external collaborators. The institute also runs clinical trials, manages technology transfer through patented devices and software, and supports spin-off biotech companies in oncology diagnostics and cellular therapies.

Product overview

The Instituto de Investigación Hospital 12 de Octubre (i+12) is a multidisciplinary biomedical research institute organized as a unified platform of specialized technical services rather than a single commercial product. The institute provides a comprehensive portfolio of 9 major scientific research areas encompassing 68 research groups, supported by core technical service units including Biobanco i+12 (biobank), bioinformatics, flow cytometry, genomics, proteomics, microscopy, animal facility, clinical research support, and training/simulation. The technology offering includes patented devices (12CLIP catheter system, human milk pasteurizer), software platforms (Datify data management, Coherent clinical analytics), and a growing portfolio of 4 spin-off companies (Altum Sequencing, STAb Therapeutics, TNC Terapia, Danae Urogenomics). An Innovation Support Unit (UAI) facilitates technology transfer and commercialization of research outcomes.

Differentiator

Problem solved

Functional benefit

Products and services

• Biobanco i+12
• Bioinformatics Service (Servicio de Bioinformática)
• Flow Cytometry Unit (UCF)
• Genomics Unit (Unidad de Genómica)
• Proteomics Unit (Unidad de Proteómica)
• Microscopy Unit (Unidad de Microscopía)
• Animal Facility and Experimental Surgery (Animalario y Quirófanos Experimentales)
• Advanced Training and Simulation Center (Centro de Formación y Simulación Avanzada)
• Clinical Research Support Unit (Unidad de Apoyo a la Investigación Clínica)
• Innovation Support Unit (UAI)
• Scientific Culture and Innovation Unit (UCC+i)
• Altum Sequencing S.L. (Spin-off)
• STAb Therapeutics S.L. (Spin-off)
• TNC Terapia (Spin-off)
• Danae Urogenomics S.L. (Spin-off)

Quantifiable outcome

• 68 research groups across 9 scientific areas contributing to national and international research output
• +2 more outcomes

Named customers7 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

16 partnerships are on record, tiered core and major.

• Universidad Politécnica de Madrid (UPM)coreStrategic or Co-development Partner · 1 January 2024Joined institute in 2024 contributing digital transformation and biomedical engineering expertise. Active in Digital Transformation research area and electronic design.
• Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT)coreStrategic or Co-development Partner · 1 January 2015Joined institute in 2015 contributing energy, environmental and technological research expertise. Active in areas including cancer research and biomedical engineering.
• Universidad EuropeacoreStrategic or Co-development Partner · 1 January 2015Joined institute in 2015 contributing research and education capabilities. Partners in transversal research areas including physical activity and health.
• Universidad Complutense de Madrid (UCM)coreStrategic or Co-development Partner · 15 December 2009Founding partner of the institute established December 15, 2009. Contributes teaching faculty and research groups across multiple scientific areas including cancer, neurosciences, cardiovascular, and infectious diseases. Multiple UCM researchers serve as coordinators of institute research areas.
• Universidad Autónoma de Madrid (UAM)coreStrategic or Co-development Partner · 15 December 2009Founding partner contributing research groups to the institute. Collaborates in basic and clinical research across multiple disease areas.
• Servicio Madrileño de SaludcoreStrategic or Co-development Partner · 15 December 2009Founding institutional partner providing healthcare system integration and access to patient populations through Hospital Universitario 12 de Octubre.
• Fundación para la Investigación Biomédica del Hospital 12 de Octubre (FIBH12O)coreStrategic or Co-development Partner · 15 December 2009Management entity of the institute responsible for administrative, financial, and scientific management. Acts as contracting entity for clinical trials and research projects.
• Agencia de Formación, Investigación y Estudios Sanitarios Pedro Laín EntralgocoreStrategic or Co-development Partner · 15 December 2009Founding regional government partner providing institutional support and coordination for health research and training programs.
• ITEMAS - Plataforma de Dinamización e Innovación de las Capacidades Industriales del SNScoreStrategic or Co-development PartnerPlatform promoted by ISCIII to facilitate technology transfer from health professionals. Institute participates through Innovation Support Unit (UAI i+12) providing innovation management and commercialization support.
• CIBERER - Centro de Investigación Biomédica en Red de Enfermedades RarasmajorStrategic or Co-development PartnerNational biomedical research network for rare diseases. Institute researchers participate in CIBERER-funded projects and collaborative research.
• CIBERES - Centro de Investigación Biomédica en Red de Enfermedades RespiratoriasmajorStrategic or Co-development PartnerNational network for respiratory disease research. Contributes to cooperative research projects and knowledge sharing in respiratory medicine.
• CIBERNED - Centro de Investigación Biomédica en Red Enfermedades NeurodegenerativasmajorStrategic or Co-development PartnerNational network for neurodegenerative disease research. Supports collaborative projects in neurosciences and mental health.
• CIBERSAM - Centro de Investigación Biomédica en Red de Salud MentalmajorStrategic or Co-development PartnerNational mental health research network. Facilitates collaborative research in psychiatric and mental health areas.
• CIBER-BBN - Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y NanomedicinamajorStrategic or Co-development PartnerNational network for bioengineering, biomaterials and nanomedicine. Supports research in intelligent biomaterials and regenerative medicine.
• SCReN - Spanish Clinical Research NetworkmajorStrategic or Co-development PartnerNational clinical research network providing infrastructure for academic clinical trials. Supports institute's clinical research capabilities.
• Centro Integral de Cáncer del Hospital Universitario 12 de Octubre (CCC)coreStrategic or Co-development PartnerStrategic cancer center integrating care, research, and teaching in oncology. Institute contributes coordinated cancer research through integrated ecosystem with UCM.

Scale indicators6 records

Recent moves17 records

Expansion highlights6 records

Direct peers

• IRB Barcelona: Catalan biomedical research institute focused on fundamental and translational research in oncology, metabolism, and cell biology. Direct peer: comparable biomedical research scope with strong industry collaboration and technology transfer output.
• Institut d'Investigació Biomèdica de Bellvitge (IDIBELL): Catalan research institute affiliated with Hospital Universitari de Bellvitge and Universitat de Barcelona. Direct peer: similar ISCIII-accredited translational research model with comparable platform services (biobank, genomics) and oncology focus.
• Instituto de Investigación Hospital Universitario La Paz (IdIPaz): Madrid-based ISCIII-accredited research institute affiliated with Hospital Universitario La Paz. Direct peer: comparable governance model, similar Madrid public-hospital anchoring, and overlapping scientific areas in oncology, cardiovascular, and rare diseases.
• Vall d'Hebron Institut de Recerca (VHIR): Barcelona-based research institute linked to Hospital Universitari Vall d'Hebron and accredited by ISCIII. Direct peer: comparable structure combining hospital, university partners, and biomedical research areas; competes for the same CIBER networks and EU funding.
• Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC): ISCIII-accredited research institute anchored at Hospital Clínico San Carlos in Madrid. Direct peer: similar public-hospital-based translational model with multi-university integration and shared competitive pool for ISCIII funding.
• Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM): Madrid-based ISCIII-accredited health research institute linked to Hospital General Universitario Gregorio Marañón. Direct peer: shares the same ISCIII accreditation framework, multi-university consortium model, and translational research focus across similar disease areas.

Emerging players

• Centro Nacional de Investigaciones Cardiovasculares (CNIC): Spanish national center for cardiovascular research co-located with Hospital Universitario 12 de Octubre's broader campus ecosystem. Partial overlap: shares Madrid translational ecosystem and partners with i+12 via shared spin-offs (TNC Terapia).

Broad incumbents

• Karolinska Institutet: Sweden's leading medical university with extensive translational research infrastructure and academic medical center affiliations. Broad incumbent reference point: global benchmark for the university-hospital research institute model that i+12 emulates.
• Centro Nacional de Investigaciones Oncológicas (CNIO): Spain's national cancer research center. Broad incumbent: operates at a larger national scale in oncology with overlapping translational themes and shared spin-off activity (TNC Terapia), but with broader scope than i+12's regional, hospital-based model.

Others

• Centro de Investigación Biomédica en Red (CIBER): ISCIII-funded thematic network consortium of which i+12 is a member across CIBERER, CIBERES, CIBERNED, CIBERSAM, and CIBER-BBN. Adjacent: not a single competitor but the funding/distribution platform through which i+12 accesses collaborative research revenue and clinical trial infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/instituto-de-investigaci%C3%B3n-hospital-12-de-octubre

Revenue estimate

Valuation estimate

Number of profiles

Profiles21 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Instituto de Investigación Hospital 12 de Octubre